耳鼻と臨床
Online ISSN : 2185-1034
Print ISSN : 0447-7227
ISSN-L : 0447-7227
扁桃炎に対するCeftazidimeの基礎的・臨床的検討
馬場 駿吉島田 純一郎征矢野 薫小林 武弘鈴木 賢二岩田 重信高須 昭彦八井田 昌志横井 昌哉桜井 一生西村 忠郎八木沢 幹夫鈴木 昭男大屋 靖彦横田 明伊藤 弘美本堂 潤小出 明美高木 一平田中 悦夫月山 昌夫友松 えり子杉山 和子高野 剛河合 孝宮本 直哉森部 一穂小山 賢吾北條 郷明木下 治二山本 真一郎丸尾 猛東内 朗稲垣 光昭板谷 知己和田 正樹波多野 努柘植 勇人板谷 純孝鈴木 康夫堀部 幸元丹羽 珠実中西 泰夫戸田 均大森 琢也松永 仁毅出口 浩一
著者情報
ジャーナル フリー

1988 年 34 巻 6 号 p. 1520-1534

詳細
抄録

For objective evaluation of clinical efficacy and safety in lacunar tonsillitis, peritonsillitis and peritonsillar abscess, ceftazidime (CAZ) was examined for distribution of sensitivity of clinical strains, tonsillar tissue transfer, and also its clinical usefulness was examined in a multicentre clinical study using the same protocol. 1. CAZ completely inhibited growth of 53 clinical strains of gram-positive bacteria (27 of which were S. pyogenes) and 21 of gram-negative bacteria (14 were B. catarrhalis) isolated from patients with tonsillitis, at the concentrations not higher than 3.13μg/ml and 0.78μg/ml, respectively. 2. Following the intravenous administration of 1g CAZ, the mean tonsillar tissue level was 17.3μg/g (2.6-36.3μg/g, n=19) at 15-240 minutes. The mean ratio of tissue level to serum level was 40.8% (33.8-61.5%). The tissue level reached its peak at 15-22 minutes after administration and then gradually decreased. At 240 minutes after administration, however, the level was still 2.6μg/g. 3. In the clinical evaluation, 83 patients received CAZ. Clinical effectiveness and usefulness were evaluated in 78 patients, and safety in 80. The dose of CAZ was 1g twice daily in most of the 80 patients in the safety evaluation (65, 81.3%), and the duration of administration was 3 to 5 days in 43 patients, 53.8%. 4. Clinical efficacy rate (‘Excellent’ and ‘Good’) assessed by the Efficacy Assessment Committee was 94.9% (74/78) and that by the doctors in charge was 100%. The percentage of ‘Excellent’ cases was 61.5% in the assessment by the Committee and 67.9% in the doctors' assessment. As for bacteriological response, all the strains isolated before CAZ administration were eliminated, except for those from 3 patients whose response was unknown. 5. No clinical adverse event was observed in any of the 80 cases evaluated. Elevation of serum transaminases (4 cases), increase in eosinophil count (2 cases) and increase in platelet count (1 case) were observed in the laboratory tests, but none of them were serious. In conclusion, CAZ is considered to be highly useful in the treatment of tonsillitis.

著者関連情報
© 耳鼻と臨床会
前の記事 次の記事
feedback
Top